Boylan J F, Jackson J, Steiner M R, Shih T Y, Duigou G J, Roszman T, Fisher P B, Zimmer S G
Department of Microbiology and Immunology, University of Kentucky Medical Center, Lexington 40536-0084.
Anticancer Res. 1990 May-Jun;10(3):717-24.
Recent experimental evidence indicates that the c-Ha-ras (rasH) oncogene may be causally involved in the etiology and evolution of specific human neoplasms. In addition, cultured cells transformed by the rasH oncogene can induce both a tumorigenic and a metastatic phenotype when expressed in appropriate cultured cells. To begin to define the molecular and biochemical mechanism(s) by which the rasH oncogene induce their effects on expression of the transformed state we have employed a cloned rat embryo fibroblast (CREF) cell line. Transformation of CREF cells with wild-type 5 adenovirus (Wt) results in transformed cells which display anchorage-independence and an increased saturation density in monolayer culture, but are non-tumorigenic in both athymic nude mice and syngeneic Fischer rats. In contrast, when CREF cells are transformed with mutant type 5 adenoviruses, such as H5hrl, or the ElA transforming gene from hrl (0-4.5), tumors are induced in both nude mice and syngeneic rats. However, hrl (0-4.5)-transformed CREF cells are not metastatic following intravenous injection into the tail vein of syngeneic rats. Insertion of an activated T24 rasH oncogene or a wild-type v-rasH oncogene into CREF, wt-transformed CREF or hrl (0-4.5)-transformed CREF cells results in acquisition of a metastatic phenotype by these cells. A mutant v-rasH oncogene (mutant 116K), which is defective in GTP binding and the induction of transformation of NIH 3T3 cells, does not induce transformation in CREF cells, but it can progress wt-transformed CREF cells to a tumorigenic-non-metastatic state. Employing this model system which displays well-defined and stable stages in the tumor cell progression lineage, we have analyzed the potential role of changes in the phosphatidylinositol (PI) cycle and phospholipase A2 (PLA2) enzyme activity during progression to a tumorigenic and metastatic phenotype. An increase in PI cycle intermediates (primarily inositol triphosphate; IP3) were observed only in the wt-transformed and hrl (0-4.5)-transformed CREF cell lines transfected with the rasH oncogene. In the case of PLA2, all rasH-transformed CREF cell lines displayed increased activity. In contrast, CREF cells transformed only by Ad5 (Wt or hrl (0-4.5)) or the 116K v-rasH oncogene did not display increased PLA2 activity similar to that observed in rasH transfected cells. Since one important metabolite generated by PLA2 is arachidonic acid, which is converted into prostaglandins and leukotrienes by cyclooxygenase or lipooxygenase, respectively, the levels of prostaglandin E2 (PGE2) in the various cell lines were monitored.(ABSTRACT TRUNCATED AT 400 WORDS)
最近的实验证据表明,c-Ha-ras(rasH)癌基因可能在特定人类肿瘤的病因和演变中起因果作用。此外,由rasH癌基因转化的培养细胞在适当的培养细胞中表达时,可诱导致瘤和转移表型。为了开始确定rasH癌基因诱导其对转化状态表达影响的分子和生化机制,我们采用了一种克隆的大鼠胚胎成纤维细胞(CREF)系。用野生型5型腺病毒(Wt)转化CREF细胞会产生转化细胞,这些细胞在单层培养中表现出不依赖贴壁生长和增加的饱和密度,但在无胸腺裸鼠和同基因的Fischer大鼠中均无致瘤性。相比之下,当CREF细胞用突变型5型腺病毒(如H5hrl)或来自hrl的E1A转化基因(0-4.5)转化时,在裸鼠和同基因大鼠中都会诱导肿瘤形成。然而,hrl(0-4.5)转化的CREF细胞经尾静脉注射到同基因大鼠体内后不会转移。将活化的T24 rasH癌基因或野生型v-rasH癌基因插入CREF、wt转化的CREF或hrl(0-4.5)转化的CREF细胞中,会导致这些细胞获得转移表型。一种在GTP结合和诱导NIH 3T3细胞转化方面有缺陷的突变型v-rasH癌基因(突变体116K),在CREF细胞中不会诱导转化,但它可以使wt转化的CREF细胞发展为致瘤但不转移的状态。利用这个在肿瘤细胞进展谱系中表现出明确且稳定阶段的模型系统,我们分析了在进展为致瘤和转移表型过程中磷脂酰肌醇(PI)循环变化和磷脂酶A2(PLA2)酶活性的潜在作用。仅在转染了rasH癌基因的wt转化和hrl(0-4.5)转化的CREF细胞系中观察到PI循环中间体(主要是肌醇三磷酸;IP3)增加。就PLA2而言,所有rasH转化的CREF细胞系均表现出活性增加。相比之下,仅由Ad5(Wt或hrl(0-4.5))或116K v-rasH癌基因转化的CREF细胞没有表现出与rasH转染细胞中观察到的类似的PLA2活性增加。由于PLA2产生的一种重要代谢产物是花生四烯酸,它分别通过环氧化酶或脂氧合酶转化为前列腺素和白三烯,因此监测了各种细胞系中前列腺素E2(PGE2)的水平。(摘要截于400字)